P
TAK icon

Pitcairn’s Takeda Pharmaceutical TAK Stock Holding History

Pitcairn’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,486
Closed -$227K – 515
2025
Q3 		$227K Sell
15,486
-1,893
-11% -$28.1K 0.02% 572
2025
Q2 		$269K Sell
17,379
-3,293
-16% -$48.7K 0.02% 591
2025
Q1 		$307K Buy
20,672
+3,209
+18% +$45K 0.02% 570
2024
Q4 		$231K Buy
17,463
+5,027
+40% +$69.1K 0.01% 649
2024
Q3 		$177K Sell
12,436
-115
-0.9% -$1.63K 0.01% 687
2024
Q2 		$162K Sell
12,551
-1,650
-12% -$21.8K 0.01% 694
2024
Q1 		$197K Buy
14,201
+870
+7% +$12.7K 0.01% 690
2023
Q4 		$190K Buy
+13,331
New +$189K 0.01% 651
2023
Q3 		– Sell
-10,045
Closed -$158K – 680
2023
Q2 		$158K Buy
+10,045
New +$165K 0.01% 634

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pitcairn's TAK Position: Q4 2025 in Review

Pitcairn sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 15,486 shares — an estimated $227K sold.

Pitcairn first reported a position in TAK in Q2 2023 and held it in 9 quarters. The position peaked at $307K in Q1 2025. 348 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • Pitcairn reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 15,486 Takeda Pharmaceutical shares in Q4 2025, an estimated $227K.
  • Pitcairn first reported a position in Takeda Pharmaceutical in Q2 2023 and held it in 9 quarters.
  • Pitcairn's Takeda Pharmaceutical position peaked at $307K in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.